Dollar General Corporation (NYSE: DG), a leading discount retailer, reported first-quarter fiscal 2023 earnings per share (EPS) of $2.34, slightly below the consensus estimate of $2.38. 

The company acknowledged a more challenging macroeconomic environment than initially anticipated and revised its outlook for the fiscal year 2023. Dollar General now expects a decline of approximately 8% to flat in diluted EPS, compared to its previous projection of 4% to 6% growth for the full year.

During pre-market, $DG was trading at $182.65, experiencing a significant decrease of $18.44 (-9.17%).

Macy's, Inc. (NYSE: M), a renowned department store chain, reported first-quarter 2023 adjusted EPS of $0.56, surpassing the consensus estimate of $0.45. 

However, the company has adopted a cautious approach for the remainder of the year and adjusted its annual 2023 sales and earnings guidance to account for anticipated macroeconomic impacts on consumer behavior. Macy's now expects its adjusted diluted EPS for FY23 to fall within the range of $2.70 to $3.20, compared to the previous guidance of $3.67 to $4.11.

$M was trading at $12.38 in pre-market, showing a decline of $1.21 (-8.90%).

Pharming Group N.V. (Nasdaq: PHAR), a biopharmaceutical company, announced a definitive agreement with Novartis Pharma A.G. to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for a one-time payment of approximately US$21.1 million. 

The pediatric voucher is designed to incentivize the development of treatments for children with rare and life-threatening diseases. Holders of the voucher are granted priority review of a single New Drug Application or Biologics License Application, which expedites the review process and could lead to accelerated approval.

$PHAR closed at $12.00 on Wednesday, with a decrease of $0.10 (-0.83%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)